Cosmos Pharmaceutical

Company history

Founded
1973
Head office
Fukuoka, Japan
Listed
2004 · TSE 3349
Founder
Masaaki Uno
Revenue · FYE Mar 2025
$6.8B (¥1.01tn)
Net profit · FYE Mar 2025
$206.5M (¥31bn)
Cosmos Pharmaceutical: long-term performance & turning pointsSales (¥ bn)Net margin (%)

1973From a Nobeoka pharmacy to a new store format

Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports & corporate yearbooks
FY2001 · unconsolidated
Revenue$101M
Net income$494K
Net margin0.5%
FY2004 · consolidated
Revenue$549M
Net income$9M
Net margin1.6%
  1. 1973Masaaki Uno opens the Uno Kaitendo pharmacy in Nobeoka
  2. 1983Incorporated as Cosmos Pharmaceutical (still a 66 m² shop)
  3. 1993First small-trade-area mega drugstore; multi-store rollout begins
  4. 2003Abolishes loyalty points; shifts to everyday low prices
  5. 2004Completes Kyushu; lists on the TSE Mothers market

Cosmos began in 1973 as a single small pharmacy. Masaaki Uno, a pharmacist who had studied at the Tokyo University of Pharmacy and returned to his home town of Nobeoka in Miyazaki Prefecture, opened a 66-square-metre shop called Uno Kaitendo. For two decades he had no ambition to change the trade: he ran a handful of small neighbourhood pharmacies as a sole proprietor, and even after incorporating as Cosmos Pharmaceutical in 1983 the sales floor stayed 66 square metres. The first twenty years were a long, patient run-up — a local druggist who did not yet reach for a new kind of business.

The turn came in December 1993. In the prefectural capital of Miyazaki City, Uno opened a 600-square-metre store and began building out multiple outlets in earnest. Under one roof it carried medicines and cosmetics alongside food and daily necessities — a clear proposition that a household could buy its everyday consumables in a single trip, inside a small catchment of ten to twenty thousand people. Rather than nurture a few star stores, Uno standardised every outlet; he fixed a 1,000-square-metre format in 1999 and a 2,000-square-metre one in 2003, and settled on suburban residential areas rather than city centres. What emerged was a format of Cosmos’s own — the small-trade-area mega drugstore.

Price was the other half of the design. Influenced by regular meetings with Hidejiro Fujiwara, then chairman of the apparel chain Shimamura, Uno judged that the loyalty-point scheme he had pioneered in 1994 rewarded price-sensitive shoppers who stocked up on bargain days while penalising the loyal customer who came every day. So he moved ahead of the industry: he scrapped daily bargain sales in 2001 and abolished loyalty points altogether in 2003, converting fully to everyday low prices. The timing was deliberate — he absorbed the short-term drop in sales while still private, so that after listing investors would see only the gains. In July 2004 the chain completed its coverage of every prefecture in Kyushu, and that November it listed on the TSE Mothers market — thirty-one years after the first small pharmacy.

Read the full history in Japanese →


2005Contiguous dominance across Japan

Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports & corporate yearbooks
FY2005 · consolidated
Revenue$714M
Net income$11M
Net margin1.5%
FY2018 · consolidated
Revenue$5.1B
Net income$159M
Net margin3.2%
  1. 2005Enters the Shikoku region
  2. 2006Moves to the First Section of the Tokyo Stock Exchange
  3. 2010Enters the Kansai region
  4. 2015Enters the Chubu region
  5. 2017Revenue passes $4.5B (¥500bn)
  6. 2018Hideaki Yokoyama becomes president at 37

Cosmos stepped outside Kyushu for the first time in March 2004, opening in Yamaguchi — and the way it did so defined the next fifteen years. Uno did not leap to distant big cities; he connected one new area at a time to the outer edge of his existing logistics zone, letting the network bleed outward like ink. Yamaguchi shared a daily life-sphere with Fukuoka and was easy to reach with the existing distribution network. Repeating that he would topple over if he rushed into Tokyo before his base was firm, Uno kept to the order — Shikoku in 2005, Hiroshima and Okayama in 2007, the Kansai region in 2010, Chubu in 2015, Hokuriku in 2018 — one prefecture at a time.

That the same store format worked region by region settled an old doubt. Sceptics had said the small-trade-area mega drugstore succeeded only because of Kyushu’s peculiarities; the unbroken run of results across Chugoku, Shikoku and Kansai disproved it. Everyday low prices and one-stop buying of daily goods were accepted whatever the catchment. The chain that had 193 stores and $903M (¥105bn) in revenue when it moved to the First Section of the Tokyo Stock Exchange in 2006 had grown past 850 stores and $5.1B (¥558bn) by the year ended May 2018.

Succession proved harder than expansion. In August 2017, Uno — then seventy — moved up to chairman and named not his eldest son but Futoshi Shibata, a long-serving corporate-planning executive, as president. After a downward revision to full-year results, Shibata left the post after only ten months. In June 2018 the presidency went to Hideaki Yokoyama, aged thirty-seven, who had risen through the field from store-area manager to head of sales. The ten-month handover from a planning man to a field man was itself a statement: at Cosmos, the instinct for merchandising, store openings and store operations sits at the centre of management.

Read the full history in Japanese →


2019Into Kanto, and past ¥1 trillion

Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports & corporate yearbooks
FY2019 · consolidated
Revenue$5.6B
Net income$175M
Net margin3.1%
FY2025 · consolidated
Revenue$6.8B
Net income$206M
Net margin3.1%
  1. 2019Enters the Tokyo metropolitan area (Hiroo, Shibuya)
  2. 2020Record profit on pandemic stay-at-home demand
  3. 2022Moves to the TSE Prime market
  4. 2023Founder Masaaki Uno steps down from the board
  5. 2024Opens a record 139 stores in a single year
  6. 2025Passes $6.8B (¥1.01tn) — organic growth, no M&A
  7. 2026Announces entry into the hotel business

In April 2019 Cosmos opened its first store in the Kanto region, by Hiroo Station in Tokyo’s Shibuya ward; associates say Uno was glad to have lived to see it. Two months later the chain passed 1,000 stores nationwide, and in the year ended May 2020 it caught the pandemic’s stay-at-home demand to post revenue of $6.4B (¥684bn) and record profit. The Kyushu-born format worked in the country’s largest catchment from its very first year. The pace of new openings then shifted to another gear — 78 stores in the year to May 2021, 120 the next year, and a record 139 in the year to May 2024 — the logistics network and standardised operations built over twenty-five years in western Japan transferring intact to the east.

In the year ended May 2025, consolidated revenue reached $6.8B (¥1.01tn) — making Cosmos the first drugstore chain in Japan to cross ¥1 trillion on self-built store openings alone, with no M&A in fifty-two years, across 1,609 stores. While rivals merged — Matsumotokiyoshi with Cocokara Fine, Tsuruha with Welcia — Cosmos trained its own people, chose its own sites and built its own distribution. The self-reliance had a price: interest-bearing debt rose to $286M (¥43bn) as land purchases were brought in-house, and the gross margin fell from 22.5% at listing to 19.5% as food grew heavier in the mix, held in balance only by cutting the SG&A ratio by a similar amount. What did not fade with scale was the consistency of the proposition — everyday low prices and one-stop daily shopping — carried unbroken from a single Kyushu store. In January 2026 the company announced a move into hotels, a fresh test of how far it can keep expanding without buying anything.

Read the full history in Japanese →


Key decisions — the author’s view

Revenue (¥ bn) · net margin % · around FY1993

Creating the small-trade-area mega drugstore (1993)

A contrarian bet: a big box in a small trade area

The heart of this decision is that Uno turned a retail commonplace on its head — the rule that a large store belongs in a large trade area. Rather than fight over populous towns, he aimed at small trade areas where competitors were thin, and deliberately placed there a large store that carried even food. He funnelled the gross margin on drugs and cosmetics into cheap food, and dropped fresh produce to cut the handling and the labour. Not a drugstore, not a supermarket, not a convenience store, but a format that met all of those needs in a single shop — and Uno assembled it from a small provincial town. The twenty years of patience in Nobeoka can be read as the run-up to this one move.

The strength of having created the format itself did not thin as the company grew. Keep gross margins low but cut SG&A by more, and cheap prices and profit can coexist — this single design ran unbroken from one Kyushu store to ¥1 trillion in sales and some 1,600 outlets. The wholesale abolition of loyalty points in favour of everyday low prices, and the expansion of scale through self-built openings rather than M&A, can both be read as later choices made to defend this design. How to manufacture cheapness, and how to preserve that cheapness after scaling up — Cosmos’s course shows one company’s answer, one that placed the design of the store itself at the centre of competition.

Revenue (¥ bn) · net margin % · around FY2021

A discount store without a dispensing pharmacy enters insurance dispensing (2021)

How to lay a second pillar on top of the core strength

The character of this decision lies in connecting the company’s single greatest strength to a different kind of demand — without breaking the existing model. From its founding, Cosmos built its footfall on low-cost merchandising centred on food, and deliberately did not hold the insurance-dispensing business that requires pharmacists on staff. When it did move into dispensing, it was not to remake its format but to add a new use — the prescription — to the flow of customers it had already gathered. In the timing — unhurried, waiting to enter until the reimbursement system had been pared thin — one senses a discipline characteristic of this company.

That said, dispensing carries the heavy fixed cost of pharmacists’ wages, and could rub against the constitution of a company that has spent its life paring SG&A to the bone. How far the vision of handling dispensing at every store can coexist with low-cost management, and how far the “area-wide” separation of prescribing and dispensing (面分業) will spread, are not yet clear. As of this writing, co-located dispensing counters number just 53 stores, weighted toward the Kanto region. How thinly to lay a second pillar on top of the company’s own strength — the success or failure of this decision will be answered by the future reach and profitability of that co-located network.

Revenue (¥ bn) · net margin % · around FY2025

Build, don’t buy: reaching ¥1 trillion on organic openings alone (2025)

Choosing to build scale rather than buy it

The core of this decision is that the company cared, consistently, less about scale itself than about how scale was made. An acquisition takes in another firm’s stores, people and culture all at once — buying time with money — but leaves for later years the labour of re-aligning everything to a single mould. Cosmos chose, even though it took longer, to build one store at a time in its own mould, and reached ¥1 trillion without breaking the homogeneity of its format or its low cost. In this company’s habit of calling ¥1 trillion a waypoint, one senses a cast of mind that treats scale not as the goal but as a by-product of stacking up homogeneous stores. More than its rank as the fourth drugstore to reach ¥1 trillion in sales, it is the route by which it arrived there — without a single acquisition — that best reveals the character of this management.

That said, a shadow of limits falls on organic growth too. There is the debt swollen by bringing land acquisition in-house, the sluggish growth of existing stores, and the difficulty — mounting as scale grows — of holding every store to the same mould. While the industry buys time through consolidation, how long the choice to keep building stores can reconcile speed with homogeneity is a question not yet answered. Including its entry into a hotel business that uses land ill-suited to a drugstore, how far the company can hold to the principle of expanding without buying, in the next phase — that is where the true worth of this growth strategy will be tested.

Each heading links to the full Japanese analysis — background, decision and outcome, with sources.


References & sources

This is a condensed English edition. The full, source-by-source history — with the detailed narrative, financial tables, shareholders and executives — is maintained in Japanese: 日本語版(詳細)— Cosmos Pharmaceutical full history in Japanese →

  1. Cosmos Pharmaceutical Co., Ltd. — 有価証券報告書 (annual securities reports) and 決算短信 (earnings summaries), through the year ended May 2025.
  2. Nikkei Information Strategy — 日経情報ストラテジー (Nikkei BP), 2 Nov 2006: “Building the No. 1 store for customer service — ‘many purchases, many visits’ in a small trade area,” by Kawamata Hideki. Nikkei xTECH.
  3. The Nikkei — 日本経済新聞, 16 Jul 2025: “Cosmos Pharmaceutical past ¥1 trillion amid a wave of consolidation — the efficient management behind discount pricing and aggressive openings.” Nikkei.
  4. Shukan Shogyo — 週刊粧業, Feb 2024. syogyo.jp.
  5. Nihon Shokuryo Shimbun — 日本食糧新聞, 23 Aug 2024. nissyoku.co.jp.

Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; revenue charts are shown in yen. Exchange rates & sources — the full ¥/US$ table →